<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554850</url>
  </required_header>
  <id_info>
    <org_study_id>T4051</org_study_id>
    <nct_id>NCT03554850</nct_id>
  </id_info>
  <brief_title>Trevo® Retriever Registry (China)</brief_title>
  <official_title>Trevo® Retriever Registry (China)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Neurovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Neurovascular</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trevo® Retriever Registry (China) is to assess real world performance of the SDA cleared
      Trevo Retriever intended to restore blood flow in the neurovasculature by removing thrombus
      in patients experiencing ischemic stroke in China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trevo Registry (China) is a prospective, open-label, multi-center study, and it is the first
      Stryker China trial. This trial assesses real world performance of the Trevo® Retriever which
      is intended to restore blood flow in the neurovasculature by removing thrombus in subjects
      experiencing ischemic stroke. Total of 200 subjects among up to 15 sites in China local will
      participate in this trial. The primary endpoint is revascularization status assessment at the
      end of the procedure using the modified TICI score.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Revascularization status at the end of the procedure using the modified TICI score.</measure>
    <time_frame>At the end of the neuro-thrombectomy procedure (Day 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mRS (good clinical outcomes defined as mRS of 0-2)</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological deterioration</measure>
    <time_frame>24 hours</time_frame>
    <description>defined as a four or more point increase in the NIHSS score from the baseline score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of device and procedure related serious AEs</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Real World Data in China</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trevo® Retriever</intervention_name>
    <description>Stent retriever procedure</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Populations met the inclusion/exclusion criteria above
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18

          2. Subjects experiencing acute ischemic stroke due to a large vessel occlusion who are
             eligible and suitable for restoration of blood flow using any approved Trevo Retriever
             in the neurovasculature to remove thrombus

          3. Trevo Retriever is planned to be the primary mechanical neuro-thrombectomy device to
             remove the thrombus

          4. Subject or subject's legally authorized Representative (LAR) has signed the study
             Informed Consent Form

          5. Subject willing to comply with the protocol follow-up requirements

        Exclusion Criteria:

          1. mRS &gt;2

          2. Any known coagulopathy

          3. Anticipated life expectancy less than 3 months

          4. Known absolute contraindications to the use of required study medications or agents
             (e.g., heparin, aspirin, clopidogrel, radiographic contrast agents, etc.)

          5. Preexisting neurological or psychiatric disease that would prevent complete the study
             required evaluations

          6. The subject is participating in another mechanical neuro-thrombectomy device trial or
             any other clinical trial where the study procedure or treatment might confound the
             study end point.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ZhongRong Miao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Qin</last_name>
    <phone>+86 13524821775</phone>
    <email>fei.qin@stryker.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing TianTan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZhongRong Miao</last_name>
    </contact>
    <contact_backup>
      <last_name>Ligang Song</last_name>
      <email>bjsongligang@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Hospital of Shunyi District Beijing</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuehua Zhao</last_name>
      <email>tozhaoyh@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingyuan City People's Hospital</name>
      <address>
        <city>Qingyuan</city>
        <state>Guangdong</state>
        <zip>511518</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianglin Chen</last_name>
      <email>xlxychen@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pinyuan Zhang</last_name>
      <email>zhpy_76@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Puyang Oilfield General Hospital</name>
      <address>
        <city>Puyang</city>
        <state>Henan</state>
        <zip>457001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinchao Liu</last_name>
      <email>13949716400@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi People's Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiyi Zhu</last_name>
      <email>zhuqiyi@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingdao Central Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haicheng Yuan</last_name>
      <email>yuanhaicheng@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiliang Zheng</last_name>
      <email>zwltree@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wenzhou Central Hospital</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maohua Chen</last_name>
      <email>cmh18@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Yin</last_name>
      <email>76yinbo@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

